

# ▼ REAGILA®

## CARIPRAZINE TO TREAT SCHIZOPHRENIA

### Collecting drugs for schizophrenia



It does not provide any advantage over risperidone or aripiprazole in the treatment of schizophrenia.



IMPORTANT THERAPEUTIC INNOVATION



MODEST THERAPEUTIC INNOVATION



SOME ADDED VALUE IN SPECIFIC SITUATIONS



**NO THERAPEUTIC INNOVATION**



INSUFFICIENT EVIDENCE

+  
DATA SHEET

#### WHAT IS IT?

Antipsychotic

#### INDICATION

Schizophrenia in adults.

#### POSOLOGY AND METHOD OF ADMINISTRATION

The recommended starting dose is 1.5 mg once a day. The dose can be increased by 1.5 mg at a time up to a maximum of 6 mg per day. Administer with or without food.

#### EFFECTIVENESS

In two of the three short-term trials, no statistically significant differences were obtained with in comparison with placebo in the rate of responders (difference in PANSS score\*  $\geq 30\%$ ) when cariprazine doses less than 6 mg / day were used. In studies that include active comparators (risperidone and aripiprazole), the increase of their doses was not allowed. Therefore, it cannot be confirmed that optimal doses can be used. No statistically significant differences were obtained (with all doses) compared to aripiprazole despite the fact that the aripiprazole dose was not the most adequate. In the long-term control of negative symptoms (secondary variable), cariprazine showed slightly better results on negative symptoms than risperidone, but clinical relevance is unclear. It has not been compared to aripiprazole.

#### RISKS

It has a higher incidence of akathisia than its comparators, greater weight gain than aripiprazole, but a low profile of metabolic, hormonal (including prolactin) and QT prolongation. In addition, insomnia (14%) and headache (12%) were reported. Ophthalmic adverse reactions (lens opacity, blurred


vision ...) are pending of evaluation by the risk management plan. **Contraindications:** Patients with severe kidney or liver failure; concomitant administration of strong or moderate inducers and inhibitors of CYP3A4. **Warnings:** Suicidal thoughts and behaviors, dyskinesia, Parkinson's disease, neuroleptic malignant syndrome, seizures, risk of stroke and cardiovascular disorders.

#### PLACE IN THERAPEUTICS

It is one more therapeutic alternative in the treatment of schizophrenia. It has no added therapeutic value or advantages over aripiprazole or risperidone.

#### PRESENTATIONS

- Reagila® 1.5 mg 28 capsules (65.13 €).
- Reagila® 3 mg 28 capsules (65.13 €).
- Reagila® 4.5 mg 28 capsules (65.13 €).
- Reagila® 6 mg 28 capsules (65.13 €).



(\*) PANSS: (Positive and Negative Syndrome Scale).